Search
Picosulfuric acid
go.drugbank.com/drugs/DB09268ApprovedInvestigationalSodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. … The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322]
Isoflurane
go.drugbank.com/drugs/DB00753ApprovedInvestigationalVet approvedA stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
Ergometrine
go.drugbank.com/drugs/DB01253ApprovedInvestigationalAn ergot alkaloid with uterine and vascular smooth muscle contractile properties.
Synonyms: N-(α-(hydroxymethyl)ethyl)-D-lysergamide, N-(2-Hydroxy-1-methylethyl)-D-(+)-lysergamideCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTirofiban
go.drugbank.com/drugs/DB00775ApprovedInvestigationalIt is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. … Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery.
Synonyms: N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosineChlordiazepoxide
go.drugbank.com/drugs/DB00475ApprovedIllicitAn anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Mixtures: Nu-chlorax Capsules USPPentetrazol
go.drugbank.com/drugs/DB13415ApprovedWithdrawnPentetrazol, also known as pentylenetetrazole, is a gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptor antagonist that was approved by the FDA until 1982.[A254437]
Benzoctamine
go.drugbank.com/drugs/DB09021ExperimentalIt can be used as a sedative which does not depress the respiratory system, but rather stimulates it.
Synonyms: N-Methyl-9,10-ethanoanthracene-9(10H)-methanaminePozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigational[L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875] … [L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115].